BioMérieux (Suzhou) Biotech Co., Ltd, a subsidiary of bioMérieux, a global leader in in vitro diagnostics and the largest French biologicals enterprise, started construction in Suzhou New District on Dec 4, 2019.
The branch, designed as a production base for blood culture bottles, is the first of its kind to set outside North Caroline in the United States and aims to better serve the Asia-Pacific market.
The first phase of the project, with an investment of 460 million yuan ($64.9 million), is expected to be put into production in 2023, with an estimated annual output value of 200 to 300 million yuan and generating 40 million yuan of tax revenue.
Alain Mérieux, founder of bioMérieux, was one of the 10 foreigners being granted the "China Reform Friendship Award" at the celebration of the 40 years of China's reform and opening-up in 2018, affirming his contribution to the development of China's medical and health undertakings and Sino-French cooperation.
bioMérieux has always been driven by a pioneering spirit and unrelenting commitment to improve public health worldwide. The company is present in 44 countries and serves more than 160 countries. It provides diagnostic solutions that improve patient health and ensure consumer safety.
bioMérieux develops and produces in vitro diagnostic solutions (systems, reagents, software and services) for private and hospital laboratories, mainly for the diagnosis of infectious diseases. The results obtained from a patient sample (blood, urine, stool, cerebrospinal fluid and saliva) provide doctors with information to support their decisions.
For 25 years, bioMérieux has also applied the expertise acquired in the clinical sector to meeting industrial microbiology needs, making it possible to manage contamination risks in agri-food, pharmaceutical and cosmetic products, at each step of the production chain.
BioMérieux, a global leader in in vitro diagnostics, signs an agreement with Suzhou New District in April 2019. [Photo/snd.gov.cn]
